Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure

被引：46

作者：

Delaugerre, C ^{[1
]}

Valantin, MA

Mouroux, M

Bonmarchand, M

Carcelain, G

Duvivier, C

Tubiana, R

Simon, A

Bricaire, F

Agut, H

Autran, B

Katlama, C

Calvez, V

机构：

[1] Hosp Pitie Salpetriere, Dept Virol, Paris, France

[2] Hosp Pitie Salpetriere, Dept Infect Dis, Paris, France

[3] Hosp Pitie Salpetriere, Dept Internal Med, Paris, France

[4] Hosp Pitie Salpetriere, Dept Immunol, Paris, France

来源：

AIDS | 2001年 / 15卷 / 16期

关键词：

D O I：

10.1097/00002030-200111090-00016

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiretroviral treatment interruption in 20 extensively pre-treated HIV-1 patients with treatment failure led to genotype viral reversion of at least one class of drug-mutation resistance in half of the patients. The only predictive factor of reversion was found to be the duration of interruption. The outgrowth of residual wild-type virus seems not to be a true genetic reversion because drug mutations are detected rapidly at salvage therapy re-initiation.

引用

收藏

页码：2189 / 2191

页数：3

相关论文

共 11 条

[1] EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].

BOUCHER, CAB ;

VANLEEUWEN, R ;

KELLAM, P ;

SCHIPPER, P ;

TIJNAGEL, J ;

LANGE, JMA ;

LARDER, BA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) :1525-1530

[2] Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].

Deeks, SG ;

Wrin, T ;

Liegler, T ;

Hoh, R ;

Hayden, M ;

Barbour, JD ;

Hellmann, NS ;

Petropoulos, CJ ;

McCune, JM ;

Hellerstein, MK ;

Grant, RM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480

[3]

DEEKS SG, 2000, 7 C RETR OPP INF SAN

[4]

Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001

[5] Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy [J].

Harrigan, PR ;

Whaley, M ;

Montaner, JSG .

AIDS, 1999, 13 (08) :F59-F62

[6] Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen [J].

Izopet, J ;

Massip, P ;

Souyris, C ;

Sandres, K ;

Puissant, B ;

Obadia, M ;

Pasquier, C ;

Bonnet, E ;

Marchou, B ;

Puel, J .

AIDS, 2000, 14 (15) :2247-2255

[7] Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure [J].

Miller, V ;

Sabin, C ;

Hertogs, K ;

Bloor, S ;

Martinez-Picado, J ;

D'Aquila, R ;

Larder, B ;

Lutz, T ;

Gute, P ;

Weidmann, E ;

Rabenau, H ;

Phillips, A ;

Staszewski, S .

AIDS, 2000, 14 (18) :2857-2867

[8] HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment [J].

Neumann, AU ;

Tubiana, R ;

Calvez, V ;

Robert, C ;

Li, TS ;

Agut, H ;

Autran, B ;

Katlama, C .

AIDS, 1999, 13 (06) :677-683

[9] LONG-TERM PERSISTENCE OF ZIDOVUDINE RESISTANCE MUTATIONS IN PLASMA ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 OF DIDEOXYINOSINE-TREATED PATIENTS REMOVED FROM ZIDOVUDINE THERAPY [J].

SMITH, MS ;

KOERBER, KL ;

PAGANO, JS .

JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) :184-188

[10] Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype [J].

Verhofstede, C ;

Van Wanzeele, F ;

Van der Gucht, B ;

De Cabooter, N ;

Plum, J .

AIDS, 1999, 13 (18) :2541-2546